title: Regional chemotherapy in biliary tract cancers--a single institution experience.
abstract: OBJECTIVE
  The prognosis of biliary tract cancers is poor. The aim of the present report was to analyze retrospectively the effectiveness of regional chemotherapy in patients with biliary tract cancers treated at a single institution.
  
  
  METHODS
  Thirty-two patients with biliary tract cancers, 17 patients with cholangiocarcinoma and 15 patients with gallbladder carcinoma, were treated by regional administration of the chemotherapy, usually the combination of 5-fluorouracil, cisplatin and folinic acid. Eighteen patients with inoperable tumors received no surgical treatment, 10 patients were treated by palliative resection (cohort B), and 4 patients received radical surgery (cohort C).
  
  
  RESULTS
  The median survival of the patients is (mean +/- standard deviation) 14 +/- 17+ (median 7+) months for cohort A patients, 22 +/- 17+ (median 17+) months for cohort B patients, and 32 +/- 4+ (median 33+) months for cohort C patients. One-year survival was 38% (6 out of 16 patients) for cohort A, 80% (8 out of 10 patients) for cohort B, and 100% (4 out of 4 patients for cohort C). Two-year survival was 15% (2 out of 13) for cohort A, 30% (3 out of 10) for cohort B, and 100% (4 out of 4) for cohort C. One out of 12 patients (8%) in cohort A and 1 out of 10 patients (10%) in cohort B survived more than 5 years. After intraarterial chemotherapy, a significant increase was observed in the absolute numbers of CD3+, CD3+CD8+ and CD8+CD28+ lymphocytes, as well as an increase in CD3+CD4+ and natural killer lymphocytes.
  
  
  CONCLUSIONS
  Regional chemotherapy is active in controlling the disease, and seems to result in prolongation of survival in patients with biliary tract cancer. Administration of regional chemotherapy is also associated with a rise of circulating lymphocyte numbers.
authors.affiliation: Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, 500 05 Hradec Králové, Czech Republic. melichar@fnhk.cz
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Melichar
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Cerman
authors.forename: Josef
authors.initials: J
authors.lastname: Dvorák
authors.forename: Pavel
authors.initials: P
authors.lastname: Jandík
authors.forename: Jindríska
authors.initials: J
authors.lastname: Mergancová
authors.forename: Karolina
authors.initials: K
authors.lastname: Melicharová
authors.forename: Miroslava
authors.initials: M
authors.lastname: Tousková
authors.forename: Antonín
authors.initials: A
authors.lastname: Krajina
authors.forename: Zbynék
authors.initials: Z
authors.lastname: Voboril
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018153:Czech Republic; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil